News

Clinically grounded simulations reveal how chatbots can reinforce distress—pushing for safer AI standards.

Psychiatry confronts Epstein’s legacy, urging ethical accountability, prevention, and resources to address power abuse, sex trafficking, and women’s trauma worldwide.

Psilocybin for depression nears approval; clinicians must manage medication interactions, avoiding lithium and MAOIs while monitoring vital signs and blunted effects.

Why repeat psychiatric admissions persist, plus what hospital teams can do to break the cycle.

Olympic stories of joy, injury, and grit reveal lessons for psychiatry—burnout, secondary trauma, and knowing when to step back or retire.

FDA clears Bysanti, a novel atypical antipsychotic for acute bipolar I and schizophrenia, leveraging Fanapt data; US launch planned 2026.

The FDA accepts Teva’s once-monthly olanzapine injection for schizophrenia, promising steadier adherence without mandatory 3-hour monitoring.

How does MDMA-assisted therapy rewire fear circuits in PTSD and boost trust? Why has the FDA asked for more safety data? Learn more in this Special Report.

APSARD 2026 highlights: stimulant safety vs substance use, ADHD in pregnancy, and new nonstimulants.

Why artists feel like Sisyphus: therapy reveals family-driven rocks, reframes rejection, and helps creators embrace the grind with purpose.

Explore how World Day of Social Justice links poverty, war trauma, inequality, and social determinants to psychiatry—urging action beyond the clinic.

A consensus statement proposes a psychocardio response team to relieve the burden of comorbid cardiovascular and mental disease.

Psychedelic therapies surge in trials, but safety varies by substance—learn key benefits, risks, and why psychiatric history raises complications.

Alcohol, cannabis, nicotine and steroids quietly derail sleep, recovery, and focus for athlete patients.

Workers claims and ‘adjustment disorder’ diagnoses fuel chronic workplace litigation.

Rising heat and disasters strain mood, safety, and family planning—showing how climate anxiety and trauma track inequality.

How are MDMA and psilocybin reshaping PTSD and depression care? Learn more in our Psychedelics Special Report.

FDA feedback for CYC-126: anesthetic therapy with live EEG guidance aims to deliver precise relief for treatment-resistant depression.

IV DMT psychedelic SPL026 reduces major depression in phase 2a.

Explore how TMS offers a World Anti-Doping Agency-safe, nondrug option for athletes.

Active Minds is pushing for 988 Lifeline information to be shared on student IDs, boosting crisis access and youth-led policy action to curb suicide and reshape campus support.

Experts urge emotional intelligence stress tests to ensure safer conversations with chatbots.

Phase 3 trial shows COMP360 psilocybin rapidly reduces treatment-resistant depression symptoms with durable effects and good safety, as Compass moves toward FDA review.

How social media algorithms push violent clips, fueling desensitization, irritability, and compulsive scrolling—plus practical screening and treatment tips for clinicians.

Reality TV shows therapy and diagnoses as entertainment—raising stigma, misinformation, and suicide concerns. Get guidance for clinician-patient talks.

This Presidents Day, H. Steven Moffic, MD, links ICE raids to trauma and fear, urges ethical action and creative protest to protect immigrants and public mental health.

Adjunctive lithium sharply reduces relapse and suicidal ideation, and attempts in patients with bipolar disorder and major depressive disorder.

FDA reviews INmune Bio’s biomarker-enriched Phase 2b/3 plan for XPro1595.

Explore how seizure control, antiepileptics, and surgery can trigger psychosis in epilepsy, and what guides diagnosis and treatment.